Ferroptosis has emerged as a captivating mode of cell death owing to its reliance on iron-mediated lipid peroxidation and reactive oxygen species (ROS), setting it apart mechanistically from apoptosis or necrosis. Yet, the crosstalk between autophagy—especially LC3B-mediated autophagic flux—and ferroptosis in bladder cancer remains inadequately explored. This study leverages a comprehensive multimodal approach integrating cellular assays, murine xenograft models, and transcriptomics, including single-cell RNA sequencing, to unravel the molecular underpinnings by which JS-K exploits this axis to suppress tumor progression.

Cell culture experiments employing human bladder cancer lines T24 and UM-UC-3 unveiled classical hallmarks of ferroptosis upon JS-K administration. These included distinctive mitochondrial shrinkage observed via electron microscopy, excessive lipid peroxidation evidenced by malondialdehyde accumulation, an overwhelming surge in intracellular ROS, and iron overload. Concomitantly, pivotal ferroptosis safeguard proteins glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11 or xCT) were markedly downregulated, signifying a collapse of cellular antioxidative defenses.

Crucially, impairment or genetic silencing of LC3B—a core autophagy protein—dampened JS-K’s ability to induce iron build-up, oxidative damage, and consequent cell death. This elegant finding positions autophagy upstream as a facilitator rather than merely a bystander of ferroptosis in this context. The data imply that autophagic processes may selectively degrade ferritin or other iron storage complexes, incrementally raising free iron levels that catalyze lipid peroxidation and ferroptotic demise.

Extending these observations in vivo, JS-K administered to immunodeficient BALB/c nude mice bearing human bladder cancer xenografts produced significant tumor growth inhibition. Importantly, mice harboring tumors with silenced LC3B expression exhibited an attenuated therapeutic response, corroborating the mechanistic necessity of autophagy for optimal ferroptosis induction and antitumor efficacy. Histopathological assessment further confirmed altered protein expression patterns consistent with ferroptotic cell death pathways.

Interrogation of bulk and single-cell RNA-sequencing datasets from treated tumor tissues illuminated co-expression networks linking LC3B with ferroptosis-associated genes including CISD1 and nuclear receptor coactivator 4 (NCOA4). Among these, CISD1 emerged as a prognostically relevant biomarker, inversely correlating with clinical outcomes and highlighting its potential utility in stratifying patients for autophagy–ferroptosis-targeted therapies.

At the cellular level, JS-K’s release of nitric oxide initiates mitochondrial impairment by disrupting electron transport chain components, thereby exacerbating ROS generation. This metabolic insult, compounded by impaired iron metabolism, destabilizes the delicate redox equilibrium within cancer cells. The consequential depletion of GPX4 and xCT disables glutathione-dependent antioxidant systems, enabling unchecked lipid peroxide accumulation that culminates in ferroptotic death.

This research reframes the traditional view of autophagy and ferroptosis as independent processes, revealing a synergistic relationship that can be leveraged therapeutically. The dual impact of JS-K on cancer cell metabolism and survival pathways not only enhances ferroptosis but also impairs the autophagic recycling that would otherwise mitigate cellular damage—a double hit exploiting tumor vulnerabilities.

From a translational perspective, these findings offer a blueprint for the rational development of ferroptosis-based therapeutics in bladder cancer, a malignancy with few effective options beyond frontline chemotherapy. The identification of LC3B as both a mechanistic driver and biomarker enables potential patient stratification, potentially guiding personalized interventions where JS-K or similar agents might yield maximal efficacy.

Beyond direct tumor cell killing, modulation of the autophagy–ferroptosis interface may also influence the tumor immune microenvironment. Preliminary transcriptomic insights suggest that alterations in ferroptotic signaling could reshape immune cell infiltration and activation, opening avenues for combinatorial strategies incorporating immunotherapy.

Although JS-K remains at the experimental stage, its multifaceted mechanism—combining oxidative stress amplification, disruption of iron homeostasis, and suppression of antioxidant defenses—presents a compelling case for further pharmacokinetic and toxicological evaluations. Such efforts will be critical to clarify safety, dosing parameters, and therapeutic windows, paving the way for early-phase clinical trials.

Ultimately, this study propels the field toward new horizons where inducing autophagy-dependent ferroptosis could overcome resistance mechanisms that stymie conventional treatments. By illuminating this previously underappreciated axis in bladder cancer biology, the work not only offers hope for improved outcomes but also enriches the conceptual framework for future cancer drug discovery.

As the oncology community continues to grapple with lethal and refractory tumors, innovations such as JS-K-induced ferroptosis represent a paradigm shift. They underscore the necessity of targeting fundamental metabolic and survival processes, exploiting the intrinsic liabilities of cancer cells, and embracing integrated multimodal research strategies that bridge bench to bedside.

Subject of Research:
Not applicable

Article Title:
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study

News Publication Date:
25-Apr-2026

References:
DOI: 10.1093/pcmedi/pbag012

Image Credits:
Precision Clinical Medicine

Keywords:
Bladder cancer, ferroptosis, autophagy, JS-K, nitric oxide prodrug, iron metabolism, oxidative stress, LC3B, GPX4, xCT, tumor microenvironment, targeted therapy

Glycolysis, the metabolic pathway by which cells extract energy from glucose, is fundamentally reliant on a complex orchestra of enzymes, including PGP. Traditionally, inhibiting such an enzyme would be expected to disrupt energy production and cellular viability. However, the Würzburg research team led by Professor Antje Gohla found that completely knocking out PGP paradoxically increases cellular resistance to ferroptosis, an oxidative and iron-mediated cell death pathway that has garnered intense research interest in the context of cancer and neurodegenerative diseases.

Ferroptosis is characterized by the catastrophic accumulation of lipid peroxides fueled by iron, leading to membrane damage and cell demise. This form of cell death differs mechanistically and morphologically from apoptosis and necrosis and has been identified as a critical determinant in the survival or death of various cancer cells. Many aggressive and therapy-resistant tumors appear sensitive to ferroptosis, making it an alluring target for novel anticancer strategies. Conversely, excessive ferroptosis contributes to neurodegeneration and tissue damage, where protection against such oxidative assault is paramount.

The team’s investigations revealed that loss of PGP triggers a profound metabolic rewiring—a reprogramming of glucose flux through alternative pathways, particularly enhancing antioxidant production. This metabolic adaptation supports the cell’s ability to neutralize oxidative stress, effectively fortifying it against ferroptotic death. By diverting metabolic intermediates through pathways such as the pentose phosphate pathway, cells amplify the generation of reducing molecules like NADPH and glutathione, crucial for detoxifying reactive oxygen species that drive ferroptosis.

Intriguingly, to exploit PGP’s role therapeutically, Gohla’s group employed CP1 (Compound 1), previously characterized as a selective pharmacological inhibitor of PGP. Contrary to expectations, CP1 administration sensitize cells to ferroptosis rather than protecting them. Comprehensive biochemical analyses revealed that CP1 functions as a “double agent”: while inhibiting PGP enzymatic activity, it simultaneously targets FSP1 (ferroptosis suppressor protein 1), an essential antioxidative defender that protects membrane lipids from peroxidation.

FSP1 is a membrane-associated oxidoreductase that works synergistically with coenzyme Q10 to prevent lipid peroxidation, thus forestalling ferroptotic progression. CP1 induces pathological aggregation of FSP1, sequestering it away from the plasma membrane and impairing its protective function. This dual targeting obliterates two major cellular defense lines—disrupting glycolysis and disabling FSP1’s antioxidative shield—thus tipping the redox equilibrium towards lethal oxidative stress and cell death.

These findings elucidate a mechanistic interplay between metabolic regulation and ferroptosis susceptibility, underscoring the complex cellular strategies that govern survival under stress. The metabolic rerouting observed upon PGP depletion represents a defensive adaptation, while the pharmacological blockade of both PGP and FSP1 by CP1 exemplifies a novel lethality-inducing approach. Importantly, this bimodal inhibition strategy might be harnessed to selectively eradicate highly glycolytic tumors often refractory to conventional treatments.

Moreover, the insight that CP1 simultaneously targets two key regulators of ferroptosis suggests that careful molecular design of combination inhibitors could enhance therapeutic efficacy. By disrupting metabolic flux and antioxidant defenses in tandem, such drugs might induce robust, targeted cancer cell death while sparing normal tissues less dependent on glycolysis or with preserved antioxidant capacity.

On the flip side, this study prompts reconsideration of therapeutic PGP inhibition in contexts where ferroptosis is detrimental, such as neurodegeneration and ischemic injury. The unexpected increase in ferroptosis sensitivity upon pharmacological inhibition underscores the necessity for nuanced drug designs that avoid off-target effects on protective proteins like FSP1.

This pioneering work not only deepens the molecular understanding of ferroptosis regulation but also paves the way for innovative therapies that strategically manipulate metabolic and antioxidative pathways. The concept of metabolic rewiring as a cell-intrinsic defense mechanism against ferroptotic death opens exciting research frontiers for disease-modifying interventions in oncology and beyond.

Professor Gohla and her team’s research offers a compelling demonstration of how metabolic enzymes traditionally viewed within the confines of cellular energy supply can also critically influence cell fate decisions. Their findings highlight the intricate crosstalk between metabolism, oxidative stress responses, and cell death mechanisms—a trinity that holds the key to unlocking new paradigms in targeted therapy.

As the scientific community continues to unravel ferroptosis’ biological nuances, studies like this underscore the therapeutic potential of targeting metabolic vulnerabilities in cancer cells. The dual inhibition of PGP and FSP1 represents a novel mechanistic strategy to exploit the metabolic dependencies of malignant cells, potentially overcoming resistance to current therapies.

Future investigations will undoubtedly explore the broader implications of PGP and FSP1 modulation in vivo, assessing therapeutic windows, toxicity profiles, and combinatorial regimens to maximize clinical benefit. The work from Würzburg sets a compelling precedent for the rational design of multi-targeted compounds capable of selectively dismantling cancer cells’ metabolic and antioxidative shields.

In summary, the unexpected dual role of CP1 as both a PGP inhibitor and an FSP1 disruptor illustrates a sophisticated pharmacological mechanism with promising therapeutic applications. By illuminating the metabolic basis of ferroptosis resistance and sensitization, this study offers a robust framework for next-generation drug development aiming to precisely tip the cellular balance toward death in cancer, or survival in degenerative diseases.

Subject of Research: Cells
Article Title: Metabolic rewiring driven by phosphoglycolate phosphatase deletion inhibits ferroptosis
News Publication Date: 29-May-2026
Web References: 10.1126/sciadv.aeb2368
References: Science Advances journal article, DOI: 10.1126/sciadv.aeb2368
Keywords: ferroptosis, phosphoglycolate phosphatase, PGP, FSP1, glycolysis, metabolic rewiring, oxidative stress, lipid peroxidation, cancer therapy, neurodegeneration, CP1 inhibitor, oxidative cell death